Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines
Abstract
:1. Introduction
2. The Global Emergence of MS
3. Ubiquitous Application of MS Diagnostic Criteria
4. Global MS Care Disparities
5. Impact of Follow-On Therapeutic Molecules and Biosimilar Medications
6. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Rossi, S.; Studer, V.; Motta, C.; Polidoro, S.; Perugini, J.; Macchiarulo, G.; Giovannetti, A.M.; Pareja-Gutierrez, L.; Calò, A.; Colonna, I.; et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology 2017, 89, 1338–1347. [Google Scholar] [CrossRef] [PubMed]
- Isoupras, A.; Lordan, R.; Zabetakis, I. Inflammation, not Cholesterol, Is a Cause of Chronic Disease. Nutrients 2018, 10, 604. [Google Scholar] [CrossRef] [PubMed]
- Ontaneda, D.; Thompson, A.J.; Cohen, J.A. Progressive multiple sclerosis: Prospects for disease therapy, repair, and restoration of function. Lancet 2017, 389, 1357–1366. [Google Scholar] [CrossRef]
- Corboy, J.R.; Weinshenker, B.G.; Wingerchuk, D.M. Comment on 2018 American Academy of Neurology guidelines on disease-modifying therapies in MS. Neurology 2018, 90, 1106–1112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rivera, V.M. Multiple Sclerosis in Latin America: Reality and challenge. Neuroepidemiology 2009, 32, 293–295. [Google Scholar] [CrossRef] [PubMed]
- Pearson, J.F.; Alla, S.; Clarke, G.; Taylor, B.V.; Miller, D.H.; Richardson, A.; Mason, D.F. Multiple Sclerosis in New Zealand Mãori. Mult. Scler. 2014, 20, 1892–1895. [Google Scholar] [CrossRef] [PubMed]
- Heydarpour, P.; Koshkish, S.; Abtahi, S.; Moradi-Lakeh, M.; Sahraian, M.A. Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic review and Meta-Analysis. Neuroepidemiology 2015, 44, 232–244. [Google Scholar] [CrossRef] [PubMed]
- Stachowiak, J. Rising Multiple Sclerosis Rates in Middle East. Available online: https://www.msconnection.org/Blog/October-2015-rising-multiple-sclerosis-rates-in-Middle-East (accessed on 6 September 2018).
- Callegaro, D.; de Lolio, C.A.; Radvany, J.; Tilbery, C.P.; Mendonça, R.A.; Melo, A.C. Prevalence of Multiple Sclerosis in the city of Sao Paulo, Brazil, in 1990. Neuroepidemiology 1992, 11, 11–14. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez, O.; Sotelo, J. Is the Frequency of Multiple Sclerosis Increasing in Mexico? J. Neurol. Neurosurg. Psychiatry 1995, 59, 528–530. [Google Scholar] [CrossRef] [PubMed]
- Charcot, J.M. Lectures on the Diseases of the Nervous System. Delivered at la Salpêtrière; New Sydenham Society: London, UK, 1881; Volume II. [Google Scholar]
- Wood, H.C., Jr. Multiple Sclerosis: The History of a Disease; Demos Medical Publishing: New York, NY, USA, 2005; pp. 224–250. [Google Scholar]
- Alter, M.; Olivares, L. Multiple sclerosis in Mexico: An epidemiologic study. Arch. Neurol. 1970, 23, 451–454. [Google Scholar] [CrossRef] [PubMed]
- Cristiano, E.; Rojas, J.; Romano, M.; Frider, N.; Machnicki, G.; Giunta, D.; Calegaro, D.; Corona, T.; Flores, J.; Gracia, F.; et al. The epidemiology of multiple sclerosis in Latin America and the Caribbean: A systematic review. Mult. Scler. 2013, 19, 844–854. [Google Scholar] [CrossRef] [PubMed]
- De la Maza Flores, M.; Arambide Garcia, G. Prevalence of multiple sclerosis in the Municipality of San Pedro Garza García, Nuevo León (Mexico). Avances 2006, 1, 8–10. [Google Scholar]
- Nazr, Z.; Elemadifar, M.; Khalili, B. Epidemiology of Multiple Sclerosis in the Middle East. A systematic review and meta-analysis. Mult. Scler. Relat. Disord. 2014, 3, 744. [Google Scholar] [CrossRef]
- Gracia, F.; Castillo, L.C.; Benzadón, A.; Larreategui, M.; Villareal, F.; Triana, E.; Arango, A.C.; Lee, D.; Pascale, J.M.; Gomez, E.; et al. Prevalence and Incidence of multiple sclerosis in Panama (2000–2005). Neuroepidemiology 2009, 32, 287–293. [Google Scholar] [CrossRef] [PubMed]
- Ordoñez, G.; Romero, S.; Orozco, L.; Pineda, B.; Jiménez-Morales, S.; Nieto, A.; García-Ortiz, H.; Sotelo, J. Genomewide admixture study in Mexican Mestizos with multiple sclerosis. Clin. Neurol. Neurosurg. 2015, 130, 55–60. [Google Scholar] [CrossRef] [PubMed]
- Rivera, V.M. Multiple Sclerosis in Latin Americans: Genetic Aspects. Curr. Neurol. Neurosci. Rep. 2017, 17, 57–63. [Google Scholar] [CrossRef] [PubMed]
- Flores, J.; González, S.; Morales, X.; Yescas, P.; Ochoa, A.; Corona, T. Absence of multiple sclerosis and demyelinating diseases among Lacandonians, a Pure Amerindian Ethnic Group in Mexico. Mult. Scler. Int. 2012. [Google Scholar] [CrossRef] [PubMed]
- Liu, X.; Cui, Y.; Han, J. Estimating epidemiological data of Multiple Sclerosis in hospitalized data in Shandong, Province, China. Orphanet J. Rare Dis. 2016, 11, 73. [Google Scholar] [CrossRef] [PubMed]
- Kira, J. Multiple Sclerosis in the Japanese population. Lancet Neurol. 2003, 2, 117–127. [Google Scholar] [CrossRef]
- Kim, N.H.; Kim, H.J.; Cheong, H.K.; Kim, B.J.; Lee, K.H.; Kim, E.-H.; Kim, E.A.; Kim, S.; Park, M.S.; Yoon, W.T.; et al. Prevalnece of multiple sclerosis in Korea. Neurology 2018, 75, 1432–1438. [Google Scholar] [CrossRef] [PubMed]
- Boiko, A.N. Multiple sclerosis prevalence in Russia and other countries of the former USSR. In Multiple Sclerosis In Europe: An Epidemiological Update; Firmhaber, W., Lauer, K., Eds.; Leuchtturm: Darmstadt, Germany, 1994; pp. 219–230. [Google Scholar]
- Malkova, N.A.; Shperling, L.P.; Riabukhina, O.V.; Merkulova, E.A. Multiple sclerosis in Eastern Siberia: A 20-year prospective study in Novosibirsk city. Zh. Nevrol. Psikhiatr. Im. S S Korsakova 2006, 3, 11–16. [Google Scholar]
- Boyko, A.; Smirnova, N.; Petrov, S.; Gusev, E. Epidemiology of Multiple Sclerosis in Russia, a historical review. Mult. Scler. Demyelinating Dis. 2016, 1, 13. [Google Scholar] [CrossRef]
- Mohammed, E.M.A. Multiple Sclerosis is prominent in the Gulf states: Review. Pathogenesis 2016, 3, 19–38. [Google Scholar] [CrossRef]
- Inshasi, J.; Thakre, M. Prevalence of multiple sclerosis in Dubai, United Arab Emirates. Int. J. Neurosci. 2011, 121, 393–398. [Google Scholar] [CrossRef] [PubMed]
- Eskandarieh, S.; Heydarpour, P.; Elhami, S.-R.; Sahralan, M.A. Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran. Iran J. Public Health 2017, 45, 699–704. [Google Scholar]
- Najim Al-Din, A.S. Multiple Sclerosis in Kuwait: Clinical and epidemiological study. J. Neurol. Neurosurg. Psychiatry 1986, 49, 928–931. [Google Scholar] [CrossRef]
- Deleu, D.; Mir, D.; Al Tabouki, A.; Mesraoua, R.; Mesraoua, B.; Akhtar, N.; Al Hail, H.; D’souza, A.; Melikyan, G.; Imam, Y.Z.; et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult. Scler. 2013, 19, 816–819. [Google Scholar] [CrossRef] [PubMed]
- Visser, E.M.; Wilde, K.; Wilson, J.F.; Yong, K.K.; Counsell, C.E. A new prevalence study of Multiple Sclerosis in Orkney, Shetland and Aberdeen City. J. Neurol. Neurosurg. Psychiatry 2012, 83, 719–724. [Google Scholar] [CrossRef] [PubMed]
- Prevalence and Incidence of Multiple Sclerosis in Scotland. Available online: https://www.mstrust.org.uk (accessed on 6 September 2018).
- Multiple Sclerosis Canada. Available online: https://mssociety.ca (accessed on 6 September 2018).
- Dilokthornsakul, O.; Valuck, R.J.; Nair, K.V.; Corboy, J.R.; Allen, R.R.; Campbell, J.D. Multiple sclerosis in the United States commercially insured population. Neurology 2016, 86, 1014–1021. [Google Scholar] [CrossRef] [PubMed]
- Thompson, A.J.; Banwell, B.L.; Barkhof, F.; William, M.C.; Timothy, C.; Giancarlo, C.; Jorge, C.; Franz, F.; Massimo, F.; Mark, S.F.; et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018, 17, 162–173. [Google Scholar] [CrossRef]
- Poser, C.M.; Paty, D.W.; Scheinberg, L.; McDonald, W.I.; Davis, F.A.; Ebers, G.C.; Johnson, K.P.; Sibley, W.A.; Silberberg, D.H.; et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann. Neurol. 1983, 13, 227–231. [Google Scholar] [CrossRef] [PubMed]
- Fortini, A.S.; Sanders, E.L.; Weinshenker, B.G.; Katzmann, J.A. Cerebrospinal Fluid Oligoclonal Bands in the Diagnosis of Multiple Sclerosis. Am. J. Clin. Pathol. 2003, 120, 672–675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Available online: http://www.focem.org (accessed on 3 October 2018).
- Gracia, F.; Armién, B.; Rivera, V. Collaborative Multiple Sclerosis Group of Central America and Spanish Caribbean Region. Multiple Sclerosis in Central American and Spanish Caribbean Region: Should it be Recognized as a Public Health Problem? J. Epid. Prev. Med. 2017, 3, 134. [Google Scholar]
- Browne, P.; Chandraratna, D.; Angood, C.; Tremlett, H.; Baker, C.; Taylor, B.V.; Thompson, A.J. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology 2014, 83, 1022–1024. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Diaz de la Fé, A. Treatment of Multiple Sclerosis in Cuba. Centro Internacional de Rehabilitación Neurológica (CIREN): Havana, Cuba. Available online: www.ciren.cu (accessed on 4 May 2017).
- Rivera, V.M.; Medina, M.T.; Duron, R.M. Multiple Sclerosis Care in Latin America. Neurology 2014, 82, 1660–1661. [Google Scholar] [CrossRef] [PubMed]
- Available online: www.msif.org/wp-content/upload/2014/09/Atlas-of-MS (accessed on 3 October 2018).
- Rivera, V.M.; Macias, M.A. Access and barriers to MS care in Latin America. Mult. Scler. J. Exp. Transl. Clin. 2017, 3. [Google Scholar] [CrossRef] [PubMed]
- Jimenez-Pérez, C.E.; Zarco-Montero, L.A.; Castañeda-Cardona, C.; Otálora Esteban, M.; Martínez, A.; Rosselli, D. Current state of Multiple Sclerosis in Colombia. Acta Neurol. Colomb. 2015, 31, 385–390. [Google Scholar]
- Rojas, J.L.; Patrucco, L.; Cristiano, E. Current and emerging treatments for relapsing multiple sclerosis in Argentinean patients: A review. Deg. Neurol. Neuromusc. Dis. 2014, 4, 103–109. [Google Scholar]
- Cuevas, C.; Deisenhammer, F.; You, X.; Scolnik, M.; Buffels, R.; Sperling, B.; Flores Ramirez, F.; Macias Islas, M.; Sauri-Suárez, S. Low immunogenicity but reduced bioavailability of an interferon beta-1a biosimilar compared with its biological parent: Results of MATRIX, a cross-sectional multicenter phase 4 study. Biosimilars 2015, 5, 1–7. [Google Scholar]
- Meager, A.; Dolman, C.; Dilger, P.; Bird, C.; Giovannoni, G.; Schellekens, H.; Thorpe, R.; Wadhwa, M. An Assessment of Biological Potency and Molecular Characteristics of Different Innovator and Noninnovator Interferon-Beta Products. J. Interferon Cytokine Res. 2011, 31, 383–392. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Macias-Islas, M.A.; Soria-Cedillo, I.; Vazquez-Quintana, M.; Rivera, V.M.; Baca-Muro, V.I.; Lemus-Carmona, E.A.; Chiquete, E. Cost of care according to disease-modifying therapies in Mexicans with multiple sclerosis. Acta Neurol. Belg. 2013, 113, 415–420. [Google Scholar] [CrossRef] [PubMed]
- Steinberg, J.; Fragoso, Y.; Garcia Bonitto, J.R.; Guerra, C.; Rodriguez, V.; Correa, P.; Macias, M.; Novarro, N.; Vizcarra, D.; Orozco, G.; et al. Practical aspects and recommendations concerning the approval and use of biosimilar drugs for the treatment of multiple sclerosis in Latin America. In Proceedings of the X Latin American Committee for Treatments and Research in MS, Asuncion, Paraguay, 22–24 November 2018. Abstract 0098. [Google Scholar]
- Kowalek, K.; McKay, K.A.; Patten, S.B.; Fisk, J.D.; Evans, C.; Tremlett, H.; Marrie, R.A.; CIHR Team in Epidemiology and Impact of Comorbidity on Multiple Sclerosis (ECoMS). Comorbidity increases the risk of relapse in multiple sclerosis. Neurology 2017, 89, 2455–2461. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rivera, V.M. Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. Biomedicines 2018, 6, 112. https://doi.org/10.3390/biomedicines6040112
Rivera VM. Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. Biomedicines. 2018; 6(4):112. https://doi.org/10.3390/biomedicines6040112
Chicago/Turabian StyleRivera, Victor M. 2018. "Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines" Biomedicines 6, no. 4: 112. https://doi.org/10.3390/biomedicines6040112